Research

BACK TO MAIN INDEX

Hanham Health participates in approved NHS research studies through the NIHR Clinical Research Network. As part of the National Institute for Health Research, we help to provide the infrastructure that allows high-quality clinical research to take place in the NHS, so that patients can benefit from new and better treatments, and we can learn how to improve NHS healthcare for the future.

We are committed to the Department of Health’s national strategy which puts patients at the centre of all NHS related activity. To ensure that ‘patient benefit’ is not simply based on the views and options of research professionals and clinicians, the national strategy highlights the importance of involving patients, carers and the public at all stages of the research process.

Patients and public can be involved:

• As patients/participants voluntarily taking part in clinical or other well designed studies.
• As patients and public members working with research professionals and clinicians (e.g. doctors, nurses) and getting actively involved in the different stages of research and related activities.

Find out more

If you would like to be considered for any of our studies please let your GP know.

Current research studies

REDEFINE 3

Overview: The REDEFINE 3 study, funded and sponsored by Novo Nordisk, is a global clinical research project involving approximately 7,000 participants, with around 370 from the UK. The study aims to evaluate the cardiovascular safety of a new medication combination, CagriSema, in participants with established cardiovascular disease.

Participation:

• Voluntary: Participation is entirely voluntary, and your current and future treatment will not be affected if you choose not to participate.
• Eligibility: Participants must have Type 2 diabetes, a BMI over 25 kg/m², and established cardiovascular disease.
• Medical History: If interested, you may need to provide consent for your GP to share your medical history with the research team.

Study Details:

• Duration: The study will last approximately 4.5 years, including up to 27 visits to Southmead Hospital’s Learning & Research Department on Level 3.
• Randomization: Participants will be randomly assigned to receive either CagriSema or a placebo, in addition to standard care.

For more information, please follow this link to the REDEFINE 3 website or contact the research team at Southmead Hospital.

IBPI Trial

Overview: The IBPI (Integrated Bipolar Parenting Intervention) trial, sponsored by Lancaster University, is a research study aimed at evaluating the effectiveness of an online intervention for parents with bipolar disorder. The study seeks to improve children’s behavioral and emotional outcomes, enhance parents’ mood and confidence, and improve overall family functioning.

Participation:

• Voluntary: Participation is entirely voluntary, and your current and future treatment will not be affected if you choose not to participate.
• Eligibility: Participants must be parents with bipolar disorder, have a child aged 4-10 years old, and reside in the UK. Access to a computer, tablet, or mobile phone with internet is required.
• Medical History: If interested, you may need to provide consent for your GP or care coordinator to share your medical history with the research team.

Study Details:

• Duration: The study includes an initial screening, an eligibility check, and follow-up assessments at 24 and 48 weeks. Participants will be compensated for their time.
• Randomization: Participants will be randomly assigned to receive either the IBPI intervention or continue with their current treatment.

For more information, please contact the research team at ibpi@lancaster.ac.uk